Contributions to Hypertension With Androgen Deprivation Therapy

Inclusion Criteria:

-age 40+ years;
resting blood pressure <140/90 mmHg;
fasted blood glucose <126 mg/dL;
testosterone ≥400 ng/dL;
sedentary to recreationally active;
nonsmokers;
healthy as determined by medical history, physical exam, blood and urine chemistries and resting and exercise ECG during a physician supervised graded exercise treadmill test OR recent diagnosis of non-metastatic prostate cancer with plans to undergo androgen deprivation therapy;
PSA <4.00 ng/dL if in the non-cancer group;
Gleason Score ≤7 if in the prostate cancer group;
no use of medications that might influence cardiovascular function (e.g., antihypertensives, lipid-lowering medications);
willing and able to be on GnRHagonist and AR inhibitor;
not taking antioxidant vitamins, corticosteroids, or anti-inflammatory medications, or willing to stop use for four weeks prior to the start of the study;
not using exogenous sex hormones for at least one year

Exclusion Criteria:

-acute liver disease;
chronic kidney disease, serum creatinine >1.3 mg/dL, macroalbuminuria >300 mg/g of proteinuria
pre-existing or active cardiac, renal or hepatic disease, epilepsy or other seizure disorder;
diabetes, active or chronic infection, disease that affects the nervous system;
Gleason Score ≥8;
thyroid dysfunction, defined as ultrasensitive TSH <0.5 or >5.0 mU/L, volunteers with abnormal TSH values will be re-considered for participation after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement;
tobacco use within the previous 12 months